Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks

Dr. Lee Schwartzberg on HER2– HR+ Breast Cancer: Tesetaxel & Capecitabine

Posted by & filed under Uncategorized.

Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with HER2-negative, hormone receptor–positive metastatic breast cancer previously treated with a taxane (Abstract GS4-01)…. Read more »

X